The present retrospective study was thereby conducted to investigated the efficacy and safety of the BRICS sequential therapeutic regimen in PD-L1-negative metastatic non-small cell lung cancer patients harboring EGFR/ALK wild-type status. This evidence concerns the gene CD274 and non-small cell lung carcinoma.